Skip to main content

Novel Rx

      POETYK PsA-1 (one of paired deucravacitinib in PsA ph3 registration studies)

      Oral med
      Good outcomes
      Safety very good

      David Liew drdavidliew

      3 months ago
      POETYK PsA-1 (one of paired deucravacitinib in PsA ph3 registration studies) Oral med Good outcomes Safety very good but the bar is very high nowadays in PsA Questions splicing through depth of response Definitely will find a place in therapy, but where? #ACR25 LB19 @RheumNow https://t.co/iqmHQrMTYN
      POETYK PsA 1 and 2 Deucravacitinib TYK2 inhibitor Ph3 RCT
      52 wks data

      Deucra 336pts PBO 334pts then crossover wk 16 to

      Aurelie Najm AurelieRheumo

      3 months ago
      POETYK PsA 1 and 2 Deucravacitinib TYK2 inhibitor Ph3 RCT 52 wks data Deucra 336pts PBO 334pts then crossover wk 16 to 52 Pooled analysis wk 16 ACR 20 54% vs. 31% Enthesitis reduction LEI 52% vs. 45% Dactylics resolution 58% vs. 44% POETYK-PsA 1 Wk 52 ACR 20 63% ACR50 44% PASI https://t.co/LYJbU8fYwI
      In POETYK PsA-1, deucravacitinib showed sustained efficacy through Week 52 in PsA, improving joint, skin, PROs, and radi

      Antoni Chan MD (Prof) synovialjoints

      3 months ago
      In POETYK PsA-1, deucravacitinib showed sustained efficacy through Week 52 in PsA, improving joint, skin, PROs, and radiographic progression. Safety remained favorable with no new signals. TYK2 inhibition continues to show promise. Abstract#LB20 @RheumNow #ACR25 https://t.co/sGkk062HqJ
      Questions #ACR25 LB20 to Paul Emery on rosnilimab:
      Fleischmann: could be induction therapy? (Not intent, but could be)
      C

      David Liew drdavidliew

      3 months ago
      Questions #ACR25 LB20 to Paul Emery on rosnilimab: Fleischmann: could be induction therapy? (Not intent, but could be) Choy: Depth of changes with translational data Tanaka: Safety given peresolimab ph2b here (diff epitope, membrane proximity, targeted depletion PD-1hi) @RheumNow
      Mease et al. 52 week results deucravacitinib in PsA. Approx ACR20 60%, ACR50 40%, ACR70 25%. Sustained radiographic bene

      Richard Conway RichardPAConway

      3 months ago
      Mease et al. 52 week results deucravacitinib in PsA. Approx ACR20 60%, ACR50 40%, ACR70 25%. Sustained radiographic benefit. No new safety signals @RheumNow #ACR25 Abstr#LB20 https://t.co/vKqjb08mI8
      PD-1 agonist as an induction therapy in refractory RA??

      Rosnilimab ph2b:
      - still responding 3mo after Rx stopped
      - no d

      David Liew drdavidliew

      3 months ago
      PD-1 agonist as an induction therapy in refractory RA?? Rosnilimab ph2b: - still responding 3mo after Rx stopped - no difference between type of prior b/tsDMARD failure - safety here looks good *so far* A lot of cautious excitement in the room for this #ACR25 LB19 @RheumNow https://t.co/CmfPlP4g0N
      A new approach in RA:

      Rosnilimab targets & depletes PD-1–high pathogenic T cells, acting upstream of cytokine pa

      Jiha Lee JihaRheum

      3 months ago
      A new approach in RA: Rosnilimab targets & depletes PD-1–high pathogenic T cells, acting upstream of cytokine pathways. In Ph2b, all doses improved DAS28-CRP & ACR responses vs placebo, with durable efficacy & good safety. @RheumNow #ACR25 Abstract#LB19 https://t.co/cIxi7NEu6C
      #ACR25 Abstr#LB19 New T-cell therapy on the block! In Phase 2b RCT of #RA (~50% b/tsDMARD-IR), Rosnilimab, PD-1 agonist

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 months ago
      #ACR25 Abstr#LB19 New T-cell therapy on the block! In Phase 2b RCT of #RA (~50% b/tsDMARD-IR), Rosnilimab, PD-1 agonist met its endpoint (DAS28-CRP) at WK12. Effective despite type of previous therapy. No safety concern/malignancy/death. To proceed to Phase 3 @RheumNow #ACRBest https://t.co/MecTYMpH0o
      Emery et al. Rosnilimab, selective T cell (PD-1high Tph/Tfh, Teff) monoclonal antibody in RA. Phase 2 RCT. 424 patients.

      Richard Conway RichardPAConway

      3 months ago
      Emery et al. Rosnilimab, selective T cell (PD-1high Tph/Tfh, Teff) monoclonal antibody in RA. Phase 2 RCT. 424 patients. 41% prior bDMARD. 69% CDAI LDA week 14. Week 12 ACR20 70%, ACR50 40%, ACR70 21%. @RheumNow #ACR25 Abstr#LB19 https://t.co/479q6COWvk
      ROC-SpA Study
      Psoriatic arthritis (PsA) is a complex inflammatory disease often complicated by obesity, which not only worsens disease activity but also impairs treatment response. At ACR Convergence 2025, three compelling studies spanning pharmacologic, lifestyle, and longitudinal observational data converged on a central theme: weight loss is a powerful modulator of PsA outcomes, regardless of the intervention used.
      IgG4 is a rare autoimmune disease with excessive IgG4 immunoglobulins that can affect multiple organs yielding plasma cell deposition (inflammation) and fibrosis.There has been great progress in treatment. Traditionally, glucocorticoids were used and if ineffective, then an oral immunesuppressive (ex: Azathioprine, MMF) and, if needed, rituximab. Many patients can improve sufficiently on this regimen.
      #ACR25 Abstr#LB14 Promising therapyBMS-986353, a CD19 CAR-T in Severe Refractory Idiopathic Inflammatory Myopathies. 11

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 months ago

      #ACR25 Abstr#LB14 Promising therapy BMS-986353, a CD19 CAR-T in Severe Refractory Idiopathic Inflammatory Myopathies. 11/12 had evaluable data; muscle, skin and ILD improved. 1 x G2 CRS, 1 G3 ICANS. Longer FU needed and larger sample @RheumNow https://t.co/zAG23tAsbL

      ×